Prescient Therapeutics (ASX:PTX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Prescient Therapeutics (ASX:PTX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Update - Proposed issue of securities - PTX
Prescient Therapeutics - Extension of Share Purchase Plan
Prescient Therapeutics extends A$7 million share purchase plan to 15 September
PTX-100 CTCL Phase 2a study reaches review milestone
Prescient Therapeutics hits Phase 2a enrolment milestone for PTX-100 CTCL study, DOC review set for December 2026
Prescient Share Purchase Plan Investor Presentation
Prescient Therapeutics Opens SPP to Raise $7m Today
Prescient Therapeutics launches $7 million Share Purchase Plan to advance PTX-100 clinical development
Share Purchase Plan Cleansing Notice
Proposed issue of securities - PTX
Prescient Therapeutics Launches Share Purchase Plan for $7m
Prescient Therapeutics launches $7 million Share Purchase Plan to advance PTX-100 cancer therapy
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Prescient Therapeutics advances PTX-100 Phase 2a trial, reduces loss by 4.4%, raises $9.8M
June 2026 Quarterly Update and Appendix 4C
Prescient Therapeutics advances PTX-100 Phase 2a trial with increased enrolment and new CMO appointment
Notification of cessation of securities - PTX
PTX Dr Rosalind Wilson appointed as Chief Medical Officer